Integrin antagonists are effective and safe for Crohn's disease: a meta-analysis.
World J Gastroenterol
; 21(15): 4744-9, 2015 Apr 21.
Article
en En
| MEDLINE
| ID: mdl-25914486
ABSTRACT
AIM:
To evaluate the efficacy and safety of integrin antagonists, including natalizumab and vedolizumab, in Crohn's disease (CD).METHODS:
We carried out a literature search in PubMed, MEDLINE, EMBASE and the Cochrane Library to screen for citations from January 1990 to August 2014. Data analysis was performed using Review Manager version 5.2.RESULTS:
A total of 1340 patients from five studies were involved in this meta-analysis. During 6-12 wk treatment, integrin antagonists increased the rate of clinical response and remission with OR = 1.69, 95%CI 1.37-2.09 and 1.84, 95%CI 1.44-2.34, respectively. No significant difference was found between integrin antagonists and placebo treatments regarding their adverse reactions (OR = 1.07, 95%CI 0.83-1.38) and serious adverse reactions (OR = 0.81, 95%CI 0.57-1.15).CONCLUSION:
The results prove the efficacy and safety of integrin antagonists for CD treatment, although the treatment strategies varied.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Fármacos Gastrointestinales
/
Enfermedad de Crohn
/
Integrinas
/
Antiinflamatorios
Tipo de estudio:
Clinical_trials
/
Diagnostic_studies
/
Etiology_studies
/
Risk_factors_studies
/
Systematic_reviews
Límite:
Adult
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
World J Gastroenterol
Asunto de la revista:
GASTROENTEROLOGIA
Año:
2015
Tipo del documento:
Article
País de afiliación:
China